Lung large cell neuroendocrine carcinoma(LCNEC)is a rare and highly aggressive tumor,with the majority of patients diagnosed at an advanced stage.Despite the low incidence of LCNEC,the lack of specific treatments and epidemiological data has led to a lack of uniform standards for its clinical management.Currently,patients with early-stage LCNEC are mainly treated with surgical resection,and the regimen of adjuvant chemotherapy is mainly based on small cell lung cancer.Patients with locally advanced and late-stage LCNEC are mostly treated with chemotherapy or radiotherapy-chemotherapy combinations,and the standard treatment protocol for patients with advanced LCNEC is not yet clear.The emerging classification of molecular subtypes provides a new perspective for individualized treatment,but further research is needed to provide patients with more precise treatment strategies.With the emergence of novel therapeutic strategies such as immune checkpoint inhibitors,DLL3-targeted therapy and lysosomal viral therapy,the treatment strategy for LCNEC is gradually moving toward individualization and precision.This article reviews the advances in the diagnosis and treatment of LCNEC,aiming to provide reference opinions for clinical treatment and explore future research directions.
Large cell neuroendocrine carcinoma of the lungChemotherapyImmunotherapyTargeted therapy
维普
万方数据
